JPWO2022045336A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022045336A5
JPWO2022045336A5 JP2022545758A JP2022545758A JPWO2022045336A5 JP WO2022045336 A5 JPWO2022045336 A5 JP WO2022045336A5 JP 2022545758 A JP2022545758 A JP 2022545758A JP 2022545758 A JP2022545758 A JP 2022545758A JP WO2022045336 A5 JPWO2022045336 A5 JP WO2022045336A5
Authority
JP
Japan
Prior art keywords
tandospirone
pharma
acceptable salt
composition according
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022545758A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022045336A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/031722 external-priority patent/WO2022045336A1/ja
Publication of JPWO2022045336A1 publication Critical patent/JPWO2022045336A1/ja
Publication of JPWO2022045336A5 publication Critical patent/JPWO2022045336A5/ja
Priority to JP2026072614A priority Critical patent/JP2026126306A/ja
Pending legal-status Critical Current

Links

JP2022545758A 2020-08-31 2021-08-30 Pending JPWO2022045336A1 (cg-RX-API-DMAC7.html)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026072614A JP2026126306A (ja) 2020-08-31 2026-04-24 パーキンソン病の運動合併症治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020145967 2020-08-31
PCT/JP2021/031722 WO2022045336A1 (ja) 2020-08-31 2021-08-30 パーキンソン病の運動合併症治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026072614A Division JP2026126306A (ja) 2020-08-31 2026-04-24 パーキンソン病の運動合併症治療薬

Publications (2)

Publication Number Publication Date
JPWO2022045336A1 JPWO2022045336A1 (cg-RX-API-DMAC7.html) 2022-03-03
JPWO2022045336A5 true JPWO2022045336A5 (cg-RX-API-DMAC7.html) 2024-09-04

Family

ID=80353469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545758A Pending JPWO2022045336A1 (cg-RX-API-DMAC7.html) 2020-08-31 2021-08-30
JP2026072614A Pending JP2026126306A (ja) 2020-08-31 2026-04-24 パーキンソン病の運動合併症治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026072614A Pending JP2026126306A (ja) 2020-08-31 2026-04-24 パーキンソン病の運動合併症治療薬

Country Status (10)

Country Link
US (2) US11628169B2 (cg-RX-API-DMAC7.html)
EP (1) EP4218764A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022045336A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230058615A (cg-RX-API-DMAC7.html)
CN (1) CN116113402A (cg-RX-API-DMAC7.html)
AU (1) AU2021332775A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189670A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002422A (cg-RX-API-DMAC7.html)
TW (1) TW202227080A (cg-RX-API-DMAC7.html)
WO (1) WO2022045336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (cg-RX-API-DMAC7.html) * 2020-08-31 2022-03-03

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPS58126865A (ja) 1981-12-22 1983-07-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JPH11228414A (ja) 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
JPH11228454A (ja) * 1998-02-17 1999-08-24 Sumitomo Chem Co Ltd アルキニル置換アリールブロミド類の製造方法
JP2002020291A (ja) 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 認知機能障害の治療剤
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
WO2005117886A1 (ja) 2004-06-01 2005-12-15 Hisamitsu Pharmaceutical Co., Inc. 貼付剤
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
JP4873871B2 (ja) 2005-02-28 2012-02-08 久光製薬株式会社 粘着剤及び貼付剤
WO2008044336A1 (en) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Crystal-containing adhesive preparation
EP2729176A1 (en) 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
MY169068A (en) 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP3897641B1 (en) * 2018-12-20 2023-11-15 Contera Pharma A/S Treatment of movement disorders
JP2020145967A (ja) 2019-03-13 2020-09-17 日清食品ホールディングス株式会社 プライマー及び特定昆虫の検出方法
US10758535B1 (en) 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (cg-RX-API-DMAC7.html) * 2020-08-31 2022-03-03

Similar Documents

Publication Publication Date Title
Chaudhuri et al. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?
JP6889231B2 (ja) レボドパ、ドーパミン脱炭酸酵素阻害薬およびcomt阻害薬を含む医薬組成物ならびにその投与方法
Sprenger et al. Management of motor and non-motor symptoms in Parkinson’s disease
Nyholm Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update
Dupont et al. Sustained‐release Madopar HBS® compared with standard Madopar® in the long‐term treatment of de novo parkinsonian patients
Di Stefano et al. New drug delivery strategies for improved Parkinson's disease therapy
JP7169297B2 (ja) 再発膠芽腫(rgbm)の治療方法
Khan Off spells and dyskinesias: pharmacologic management of motor complications
JP2023552700A5 (cg-RX-API-DMAC7.html)
JP6196704B2 (ja) 神経因性疾病の治療のための医薬
RU2019111096A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
Alotaibi et al. Parkinson's disease: current treatment modalities and emerging therapies
KR20230118933A (ko) 초기 특발성 파킨슨병에 대한 치료 요법
JP2025072496A (ja) ジスキネジア治療薬
JP2009506978A5 (cg-RX-API-DMAC7.html)
JP2016505050A5 (cg-RX-API-DMAC7.html)
CN105848655B (zh) 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法
Lim A walk through the management of Parkinson s disease
Todorova et al. Subcutaneous, intranasaland transdermal dopamine agonists in the management of Parkinson’s disease
Obering et al. Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson's disease
JP7485874B2 (ja) 神経変性障害の治療のための医薬組成物の連続的投与
CN101797243A (zh) 一种含有左旋多巴和冰片的组合物及其应用
Antonini New strategies in motor parkinsonism
JP2016503406A5 (cg-RX-API-DMAC7.html)
KR20250150676A (ko) 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산